Advertisement

Topics

Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies

08:00 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Patents strengthen Company’s intellectual property portfolio for its lead product candidate ASN100 which is designed to uniquely address Staphylococcus aureus infections Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopha...

Other Sources for this Article

Media:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com
or
Investors:
Michael Gray, 781-819-5201
Chief Operating and Chief Financial Officer
mike.gray@arsanis.com

NEXT ARTICLE

More From BioPortfolio on "Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...